Piramal Pharma Solutions Expands Peptide API Facility

Piramal Pharma Solutions, a worldwide CDMO, has launched an advanced spray drying suite at its designed peptide development and manufacturing facility in Turbhe, India. This strategic expansion aims to address the complex formulation challenges related to peptides and other challenging molecules and helps meet the increasing demand for these molecules.

Benefits of Spray Drying

Spray drying transforms liquid preparations into dry powders in a single step, allowing improved bioavailability, precise particle size, and processing sensitive compounds safely. This process is particularly significant for peptides, which are unstable at high temperatures and often need strict control over particle characteristics. Its gentle and effective nature is intended to allow drug developers to enhances solution, streamline scale-up, increase speed, and preserve the molecular integrity of their peptide API.

New Spray Drying Suite Capabilities

The novel spray drying suite functions as a closed-loop technology, armed with its own inert gas supply and well-developed safety measures, including specialized HVAC, airlocked entries and exits, operator isolation, and a dedicated cleaning region. This allows the safe management of potent compounds and organic solvents needing up to Band 5 containment. Also, the processing area maintains ISO Class 8 cleanliness standards, confirming strict control of the environment through processes.

Engineered for small-volume, increasing-potency batches, the unit supports a feed rate of up to 1 liter per hour. It spray-dries highly concentrated solutions, each with up to 30% water content creating it specifically suitable for the formulation of biomolecules and large peptides. Under optimal conditions, the suite is leveraged for low-volume small-molecule preparations.

“Peptides present some of the most intricate formulation challenges in pharmaceutical development, owing to their inherent instability and sensitivity to processing conditions,” said Dr. Jordi Bacardit, Global Technical Lead on Peptides and Member of the Science Collective at PPS. “Spray drying addresses these distinct challenges by allowing tight control over key components like temperature and solvent environment. With the addition of the spray drying suite at Turbhe, we can help our partners bring stable, high-quality peptide formulations to patients in need worldwide.”

According to Towards Healthcare, the small molecule innovator API CDMO market is projected to grow significantly, with estimates indicating the market size will increase from USD 28.46 billion in 2026 to approximately USD 50.54 billion by 2035. expanding at a CAGR of 6.59% from 2026 to 2035.The right CDMO biopharma collaboration brings particular expertise, scalable infrastructure, and cooperative management. This collaboration not only confirms seamless transitions from discovery to commercialization and lessens challenges, but also maximizes the strength for innovative therapies to advance patient lives. They integrate drug discovery solutions, process advancement, analytical support, and commercial production under one roof. This integrated strategy lowers hand-offs between companies, shortens timelines, confirms regulatory compliance, and supports organization bring therapies to market rapidly while maintaining consistent quality throughout the drug lifespan.

About Piramal Pharma Solutions

Piramal Pharma Limited is a worldwide pharma organization committed to well-developed medical care through high-quality, science-led products and solutions. As a trusted player in the medicinal industry, Piramal pharma collaboration with consumers and customer global to deliver innovative, reliable, and compliant products and solutions that enhance patient outcomes. Piramal Pharma operates advance amenities that support end-to-end pharmaceutical advancement and manufacturing in the drug development lifecycle. The company follows stringent worldwide quality and government standards, ensuring consistency, safety, and effectiveness in each product. Provides synthetic chemistry, analytical support, drug metabolism and pharmacokinetics (DMPK), and route scouting.

A recent report by Towards Healthcare highlights that the small molecule innovator API CDMO market is growing, as CDMOs for small molecule APIs provide benefits in improving efficiency, speeding up timelines, and lessening research and development expenses. Some pharmaceutical contract development and manufacturing organizations (CDMOs) provide synthesis of small molecule APIs, drug substance development solutions, and small molecule API contract manufacturing from cGMP clinical to commercial production. So, with increasing problems and quality standards, organizations are considering outsourcing APIs to small molecule CDMOs. CDMOs offer adaptable manufacturing capacities, enabling simple scalability to adjust to various small molecule manufacturing volumes, catering to the emerging requirements of their clients. CDMOs have advanced tools and methodologies, providing access to advanced technologies like biocatalysis and flow chemistry that are expensive for individual companies for the advancement of small molecule APIs.